secwatch.observer — SEC 8-K summary
======================================

Issuer:     CV Sciences, Inc. (CVSI)
CIK:        0001510964
Form:       8-K
Filed at:   2026-08-13T20:04:52+00:00
Accession:  0001193125-26-349136
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CV Sciences Q2 2026 revenue down 17.5% to $3.0M; adjusted EBITDA turns negative
-------------------------------------------------------------------------------

- Revenue $3.0M, down 17.5% YoY from $3.6M; gross margin 48.6% vs 50.9% prior year.
- Operating loss widened to $0.3M from $0.1M; adjusted EBITDA turned negative at -$0.1M vs +$0.1M.
- Cash balance $0.3M; operating expenses cut 11.3% YoY to $1.7M.
- 44% of net revenue from new products launched since Jan 2023; 52 new products launched; launched PlusHLTH.com e-commerce.
- U.S. Senate voted 61-32 on H.R. 6500 delaying restrictive hemp-derived cannabinoid provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1510964/000119312526349136/0001193125-26-349136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1510964/000119312526349136/cvsi-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer